Medical Microbiology and Immunology

, Volume 196, Issue 3, pp 121–125 | Cite as

HPV-vaccination against cervical carcinoma: will it really work?

  • Gerd GrossEmail author


Prophylactic HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. The quadrivalent HPV VLP 6, 11, 16, 18 vaccine (Gardasil®) and the bivalent HPV VLP 16, 18 vaccine (Cervarix®) are effective for prevention of HPV infection and cervical precancerous lesions. The quadrivalent vaccine is also effective for prevention of vulvar and vaginal lesions and genital warts. With the introduction of the vaccines general issues have to be raised such as optimal age for vaccination, duration of protection after vaccination, impact on cervical cancer screening, vaccination of males and feasibility of application to developing countries. The prospects of a vaccine which will protect against the most common viral sexually transmitted infection and thereby, protect against the complications of HPV infection such as cervical cancer is extremely appealing. The success of HPV vaccination as a major public health prevention opportunity, however, will entirely depend on efficient infrastructures to deliver the vaccines and on the acceptance by individuals, parents and health care providers.


HPV 6, 11, 16, 18 VLP vaccine (Gardasil®HPV 16, 18 VLP vaccine (Cervarix®Cervical cancer Cervical intraepithelial neoplasia Genital warts Prerequisites for success 


  1. 1.
    US Food and Drug Administration (2006) FDA licenses new vaccine for prevention of cervical cancer and other disease in females caused by human papillomavirus. FDA News, 10 AugustGoogle Scholar
  2. 2.
    Zur Hausen H (1977) Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 78:1–30 (review)Google Scholar
  3. 3.
    Durst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci 80(12):3812–3815PubMedCrossRefGoogle Scholar
  4. 4.
    FDA approves cervical cancer vaccine. (2006) American Journal of Clinical Pathology. ASCP News, August 10Google Scholar
  5. 5.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRefGoogle Scholar
  6. 6.
    Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J (1999) Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 341:1633–1638PubMedCrossRefGoogle Scholar
  7. 7.
    Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW (1996) Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70(2):960–965PubMedGoogle Scholar
  8. 8.
    Schiller JT, Lowy DR (1996) Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 7(6):373–382PubMedCrossRefGoogle Scholar
  9. 9.
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651PubMedCrossRefGoogle Scholar
  10. 10.
    Mao C, Koutsky L, Ault K, Wheeler CM, Brown DR, Wily DJ et al (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomised clinical trial. Obstet Gynecol 107:18–27PubMedGoogle Scholar
  11. 11.
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6(5):271–278PubMedCrossRefGoogle Scholar
  12. 12.
    Skjeldestad F for the FUTURE II Steering Committee, Department of Epidemiology, SINTEF Health Research, Trondheim, Norway (2005) Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil®) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. In: Abstract of the 43rd Annual Meeting of Infectious Diseases Society of America, San FranciscoGoogle Scholar
  13. 13.
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group (2006) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447):1757–1765CrossRefGoogle Scholar
  14. 14.
    Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study Group (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 15; 367(9518):1247–1255CrossRefGoogle Scholar
  15. 15.
    Pagliusi SR, Teresa Aquado M (2004) Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23:569–578PubMedCrossRefGoogle Scholar
  16. 16.
    Gross G, für das Deutsche HPV-Management-Forum (2006) Wer soll wann, wo und wie geimpft werden. Antworten des HPV.Management-Forums auf viel diskutierte Fragen, die mit Einführung von zwei unterschiedlichen HPV-Impfstoffen zur Prävention des Zervixkarzinoms und der Condylomata acuminata in Zusammenhang stehen. Dtsch Ärzteblatt 103(50):3384–3388Google Scholar
  17. 17.
    Garnett GP (2005) Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191(Suppl 1):97–106CrossRefGoogle Scholar
  18. 18.
    Hughes JP, Garnett GP, Koutsky L (2002) The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13:631–639PubMedCrossRefGoogle Scholar
  19. 19.
    Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, Ni YH, Chen CJ, Chen DS, Taiwan Childhood HCC Study Group (2005) Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 11(21):7953–7957PubMedCrossRefGoogle Scholar
  20. 20.
    Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS, Protocol 016 Study Group (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118(5):2135–2145PubMedCrossRefGoogle Scholar
  21. 21.
    Palefsky J (1995) Human papillomavirus-associated malignancies in HIV-positive men and women. Curr Opin Oncol 7(5):437–441PubMedGoogle Scholar
  22. 22.
    Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, IARC HPV Prevalence Surveys Study Group (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366:991–998PubMedCrossRefGoogle Scholar
  23. 23.
    Munoz M, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527PubMedCrossRefGoogle Scholar
  24. 24.
    Franco EL, Harper DM (2005) Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 18(23):2388–2394CrossRefGoogle Scholar
  25. 25.
    Ault KA (2006) Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Obstet Gynecol Surv 61(6 Suppl 1):S26–S31PubMedCrossRefGoogle Scholar
  26. 26.
    Zimet GD (2005) Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health 37:17–25CrossRefGoogle Scholar
  27. 27.
    Anhang R, Wright TC Jr, Smock L, Goldie SJ (2004) Women’s desired information about human papillomavirus. Cancer 15; 100(2):315–320Google Scholar
  28. 28.
    Kao JH, Chen DS (2002) Global control of hepatitis B virus infection. Lancet Infect Dis 2:395–403PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Dermatology and VenereologyUniversity of RostockRostockGermany

Personalised recommendations